Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

  1. Soriano, V.
  2. Benítez-Gutiérrez, L.
  3. Arias, A.
  4. Carrasco, I.
  5. Barreiro, P.
  6. Peña, J.M.
  7. de Mendoza, C.
Revue:
Expert Opinion on Drug Metabolism and Toxicology

ISSN: 1744-7607,  1742-5255

Année de publication: 2017

Volumen: 13

Número: 9

Pages: 1015-1022

Type: Article

DOI: 10.1080/17425255.2017.1359254 GOOGLE SCHOLAR

Objectifs de Développement Durable

La source de données: Scopus